Organon (OGN) Other financing activities (2020 - 2024)
Organon (OGN) posted quarterly Other financing activities of $2.0 million for Q4 2024, down 94.74% on a QoQ basis from $38.0 million in Q2 2024.
Organon (OGN) Other financing activities (2020 - 2024) Analysis & Trends
Organon (OGN) has reported Other financing activities for 3 consecutive years, with $2.0 million the latest figure, recorded in Q4 2024.
- In Q4 2024, Other financing activities changed N/A year-over-year to $2.0 million; the TTM figure through Dec 2025 stood at $2.0 million (down 95.0% YoY), while the FY2024 annual figure was $38.0 million, changed N/A from the prior year.
- Other financing activities came in at $2.0 million for Q4 2024 at Organon, down from $38.0 million in the prior quarter.
- The five-year high for Other financing activities was $474.0 million in Q3 2021, with the low at -$244.0 million in Q1 2021.
- Average Other financing activities over 3 years is $17.6 million, with a median of $2.0 million recorded in 2024.
- The largest YoY upside for Other financing activities was 1792.86% in 2021 against a maximum downside of 371.11% in 2021.
- Year by year, Other financing activities stood at -$171.0 million in 2020, then jumped by 377.19% to $474.0 million in 2021, then sank by 99.58% to $2.0 million in 2024.
- According to Business Quant data, Other financing activities over the past three periods registered $2.0 million, $38.0 million, and $474.0 million for Q4 2024, Q2 2024, and Q3 2021 respectively.
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) |
|---|---|---|---|---|
| 1 | Eli Lilly | 1,066.16 Bn | 1,060.88 Bn | 16.22 Bn |
| 2 | Johnson & Johnson | 611.69 Bn | 589.64 Bn | 15.96 Bn |
| 3 | AbbVie | 444.34 Bn | 434.99 Bn | 10.78 Bn |
| 4 | Astrazeneca | 284.94 Bn | 277.05 Bn | 12.61 Bn |
| 5 | Merck | 224.23 Bn | 218.58 Bn | 12.09 Bn |
| 6 | Amgen | 195.12 Bn | 183.08 Bn | 5.87 Bn |
| 7 | Gilead Sciences | 156.45 Bn | 148.73 Bn | 5.52 Bn |
| 8 | Pfizer | 136.01 Bn | 123.24 Bn | -1.21 Bn |
| 9 | Novartis Ag | 113.45 Bn | 113.67 Bn | - |
| 10 | Organon | 3.53 Bn | 2.41 Bn | 783.00 Mn |
Historic Data
Download Data| Date | Value |
|---|---|
| Dec 31, 2024 | 2.00 Mn |
| Dec 31, 2024 | 2.00 Mn |
| Jun 30, 2024 | 38.00 Mn |
| Jun 30, 2024 | 38.00 Mn |
| Sep 30, 2021 | 474.00 Mn |
| Sep 30, 2021 | 474.00 Mn |
| Jun 30, 2021 | -112.00 Mn |
| Jun 30, 2021 | -112.00 Mn |
| Mar 31, 2021 | -244.00 Mn |
| Mar 31, 2021 | -244.00 Mn |
| Dec 31, 2020 | -171.00 Mn |
| Dec 31, 2020 | -171.00 Mn |
| Sep 30, 2020 | -28.00 Mn |
| Sep 30, 2020 | -28.00 Mn |
| Jun 30, 2020 | 109.00 Mn |
| Jun 30, 2020 | 109.00 Mn |
| Mar 31, 2020 | 90.00 Mn |
| Mar 31, 2020 | 90.00 Mn |